Abstract
Signalling via the insulin-like growth factor-I receptor (IGF-IR) has been associated with resistance to anti-epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor-2 (HER-2)-based therapies in experimental systems. However, the coexpression and clinical significance of these receptors in cancer patients remain unclear. In this study, IGF-IR, EGFR, and HER-2 status was assessed retrospectively in tumor specimens from 87 Dukes' C colorectal cancer patients using immunohistochemistry (IHC). Sections were scored by the percentage of positive cells and intensity of staining. Overall, 93%, 83%, and 89% of cases expressed IGF-IR, EGFR, and HER-2, respectively. Coexpression of all three receptors was present in 75% of patients. No significant association was found between receptor expression and clinicopathological parameters or overall survival. These results indicate that coexpression of IGF-IR, EGFR, and HER-2 is common in Dukes' C colorectal cancer, supporting further investigation into co-targeting strategies.
Introduction
Targeted therapies against the Epidermal Growth Factor Receptor (EGFR) and HER-2 have significantly advanced colorectal cancer (CRC) treatment. Despite these gains, therapeutic resistance remains a major hurdle. Laboratory models suggest that "crosstalk" between signaling pathways allows cancer cells to bypass single-receptor inhibition. Specifically, the IGF-IR pathway is thought to provide a redundant survival signal when EGFR or HER-2 is blocked. This study quantifies the prevalence of these three receptors in human Dukes' C CRC samples to determine the clinical relevance of this theoretical redundancy.
Methods
The study analyzed archived tumor specimens from 87 patients with node-positive (Dukes' C) colorectal cancer treated between 1990 and 1998.
- Immunohistochemistry (IHC): Tumor sections were stained using monoclonal antibodies for IGF-IR, EGFR, and HER-2.
- Scoring: Staining was evaluated based on the percentage of positive cells (membrane and cytoplasmic) and intensity (0 to 3+). A threshold of >10% positive cells was used to define receptor positivity.
- Controls: MCF-7, SKBR3, and HN5 cell lines served as positive controls, while the R- cell line (lacking IGF-IR) served as a negative control.
Results
Receptor Prevalence and Coexpression
The study found a remarkably high prevalence of growth factor receptors. IGF-IR was detected in 93% of cases, EGFR in 83%, and HER-2 in 89%. Most significantly, 75% of the tumors expressed all three receptors simultaneously, suggesting that the majority of Dukes' C CRC tumors possess multiple potential signaling pathways for growth and survival.
Localization and Intensity
While the receptors were widely present, their cellular localization varied. Approximately 60% of cases showed membranous IGF-IR expression, which often exhibited high staining intensity (3+). In contrast, EGFR and HER-2 expression was predominantly cytoplasmic. This distinction may be critical for drug design, as different therapeutic agents (e.g., monoclonal antibodies vs. small-molecule inhibitors) target different cellular compartments.
Clinical Correlations
Statistical analysis revealed no significant association (P > 0.05) between the expression or coexpression of these receptors and overall patient survival. Furthermore, receptor status did not correlate with most clinicopathological parameters, although membranous IGF-IR was more frequent in smaller tumors (≤5 cm) and in patients over the age of 70.
Discussion
The high rate of coexpression (75%) for IGF-IR, EGFR, and HER-2 in Dukes' C colorectal cancer provides a biological explanation for why single-target therapies often fail. The presence of these receptors suggests that tumors have built-in redundancies; if one pathway is inhibited, others remain available to drive proliferation.
While the lack of correlation with survival suggests these receptors are not primary prognostic biomarkers at this disease stage, their near-ubiquity makes them prime candidates for therapeutic targeting. These findings strongly support the development of "combination cocktails" or multi-target inhibitors designed to simultaneously block IGF-IR and the ErbB family receptors, potentially overcoming the resistance mechanisms observed in clinical practice.
Summary updated